MINIPRESS (prolonged-release prazosin), alpha blocker

The Committee recommends the continuation of reimbursement in the treatment of arterial hypertension.

• ALPRESS and MINIPRESS have Marketing Authorisation in the treatment of arterial hypertension.
• The efficacy of prazosin in patients with mild to moderate essential arterial hypertension has only been demonstrated on the basis of a surrogate endpoint, the reduction in blood pressure. No studies of the efficacy of prazosin in terms of morbidity and mortality are currently available.
• In view of the more frequent observation of hypotension under immediate-release (IR) prazosin (MINIPRESS) than under the prolonged-release (PR) form, ALPRESS, the latter is recommended for the long-term treatment of patients with arterial hypertension. MINIPRESS is no longer used in the care of patients with hypertension.